If revenues and Verigene placements at hospitals take off, then its a screaming buy.
If not, then the company runs out of cash and shuts down (sell).
This is one of those binary situations, either rags or riches.
ethical. How do you benefit if Nanosphere shuts down? There's only 184,000 shares sold short, so I doubt you are short. Your reward is to relieve some of your anger from the time you sold NSPH at a big loss.
Your stupidity is colossal. Shut down all coal in China by 2018! LOL
You barely got through high school so became a hack for short selling hedge fund at $35K.
Pathetic low life.
Article today in the Wall Street Journal. "As China Unveils Carbon Cap-and-Trade, Challenges Loom"
Looks like China can benefit from Fuel Cell Energy's CO2 sequestration once they set up their cap and trade scheme.
T2 Biosystems has no revenues yet its market cap is 15x that of Nanosphere's. T2 Bio will compete with Nanosphere when they get their system on the market. We'll have to wait and see if T2 Bio revenues take off.
ethicalanalyst. Everybody likes your comments so much, that gosh, I'll also give you a thumbs up for your brilliance! Why are you so good?
T2 Biosystems will compete with Nanosphere in Yeast Candida sepsis.
Nanosphere claims a 2 hour sample to result, but Nanosphere doesn't tell us clearly that the sample first has to be cultured for 12 hours, making for a total of 14 hours. T2 Bio is claiming about 4-5 hours total to diagnose, so it would be faster than Nanosphere. But all these developmental stage companies mislead us in subtle ways, probably also T2 Bio, which currently doesn't have revenues. These companies are very subtle about how they communicate their weaknesses. There is a good article on Seeking Alpha about T2 Bio and on Nanosphere's need to culture the sample before its ready.
Can Nanosphere catch up and pass BioFire's Film Array, given that Film Array is growing rapidly?
Answer. Probably not but there's room for growth at both companies, since their products have been on the market for only about 2 years, and it'll be years for markets to reach maturity in the molecular diagnostics space. Some customers will chose Nanosphere's Verigene over Film Array because Verigene's Flex feature allows charging for chosen pathogens on an array instead of charging for the whole array. This is the pumper's point of view.
Can Nanosphere run out of cash and cease to be a going concern? Yes, if it doesn't raise cash, if Verigene fails at the FDA, or if sales do not materialize. This is the basher's main point
There's a new video on the Nanosphere website illustrating the Flex Test and how it works.
The cost savings are an advantage. The hospital charges just for the tests needed, not for all the tests on the panel. With the stock trading at 1x sales, the possibility that Nanosphere raises more cash and continued revenues growth, maybe the stock has bottomed.
Its criminal how companies are put on NASDAQ with no reliable guidance on its future prospects. Only the cold impersonal FOWARD LOOKING STATEMENTS.
The Nanosphere IPO opened at $280 but its now at $2.10
When it was at $280 investors loved it. Now its at $2.10 and they hate it.
First of all, there are very few shorts in this stock, only 220,000 as of Aug 31.
Its normal for cash-poor developmental stage companies to lose money and have low stock prices, that's the norm. Nanosphere is still developing its next generation Verigene and also the flex assays. These companies have the potential of running out of cash and going out of business, thus their low stock price. Sometimes they run into technical problems developing their products and run out of cash before they can solve the problems. Its key for Nanosphere to raise cash to continue their development efforts. Not only does the FDA need to clear the next generation Verigene, customers have to demand it. The newbies jumped in on FDA clearance of the Respiratory Flex Assay, not realizing that profits are still about 18 months away. The oldies who had bought at much higher prices, and were tired of pain, jumped in to sell, and thus the reversal. So the stock price reflects pain from those who had lost money and also optimism about the FDA clearance. The reality is that Nanosphere continues to make progress, but currently its revenues, although growing, are smaller than its expenses. We just have to wait for revenues to outgrow expenses and for Nanosphere to raise more cash. Concerning bashers, invariably there will be angry hornets nest of bashers, for companies with collapsed stock prices, who blame the company for their losses.